{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:33:51Z","timestamp":1789986831178,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a malignancy of immature progenitor cells. AML differentiation therapies trigger leukemia maturation and can induce remission, but relapse is prevalent and its cellular origin is unclear. Here we describe high resolution analysis of differentiation therapy response and relapse in a mouse AML model. Triggering leukemia differentiation in this model invariably produces two phenotypically distinct mature myeloid lineages in vivo. Leukemia-derived neutrophils dominate the initial wave of leukemia differentiation but clear rapidly and do not contribute to residual disease. In contrast, a therapy-induced population of mature AML-derived eosinophil-like cells persists during remission, often in extramedullary organs. Using genetic approaches we show that restricting therapy-induced leukemia maturation to the short-lived neutrophil lineage markedly reduces relapse rates and can yield cure. These results indicate that relapse can originate from therapy-resistant mature AML cells, and suggest differentiation therapy combined with targeted eradication of mature leukemia-derived lineages may improve disease outcome.<\/jats:p>","DOI":"10.1038\/s41467-021-26849-w","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T11:06:09Z","timestamp":1636628769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Steven","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan P.","family":"Oxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ghisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian M.","family":"Garwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kanellakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-1952","authenticated-orcid":false,"given":"Olivia","family":"Susanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-357X","authenticated-orcid":false,"given":"Michael J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7093","authenticated-orcid":false,"given":"Andrew C.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Kile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-5304","authenticated-orcid":false,"given":"Ross A.","family":"Dickins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"26849_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","volume":"31","author":"C Summers","year":"2010","unstructured":"Summers, C. et al. Neutrophil kinetics in health and disease. Trends Immunol. 31, 318\u2013324 (2010).","journal-title":"Trends Immunol."},{"key":"26849_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrc.2017.103","volume":"18","author":"H de The","year":"2018","unstructured":"de The, H. Differentiation therapy revisited. Nat. Rev. Cancer 18, 117\u2013127 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"26849_CR3","first-page":"90","volume":"95","author":"MS Tallman","year":"2000","unstructured":"Tallman, M. S. et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95, 90\u201395 (2000).","journal-title":"Blood"},{"key":"26849_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2008","unstructured":"Montesinos, P. et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113, 775\u2013783 (2008).","journal-title":"Blood"},{"key":"26849_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/ajh.23451","volume":"88","author":"L Ades","year":"2013","unstructured":"Ades, L. et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am. J. Hematol. 88, 556\u2013559 (2013).","journal-title":"Am. J. Hematol."},{"key":"26849_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111\u2013121 (2013).","journal-title":"N. Engl. J. Med."},{"key":"26849_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exphem.2017.04.007","volume":"52","author":"N van Gils","year":"2017","unstructured":"van Gils, N., Verhagen, H. & Smit, L. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. Exp. Hematol. 52, 12\u201323 (2017).","journal-title":"Exp. Hematol."},{"key":"26849_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2159-8290.CD-17-0399","volume":"7","author":"MR McKeown","year":"2017","unstructured":"McKeown, M. R. et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARalpha dependency targetable by SY-1425, a potent and selective RARalpha agonist. Cancer Discov. 7, 1136\u20131153 (2017).","journal-title":"Cancer Discov."},{"key":"26849_CR9","doi-asserted-by":"crossref","unstructured":"Lewis, A. C. & Kats, L. M. Non-genetic heterogeneity, altered cell fate and differentiation therapy. EMBO Mol. Med. 13, e12670 (2021).","DOI":"10.15252\/emmm.202012670"},{"key":"26849_CR10","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","volume":"120","author":"A Sexauer","year":"2012","unstructured":"Sexauer, A. et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML. Blood 120, 4205\u20134214 (2012).","journal-title":"Blood"},{"key":"26849_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","volume":"3","author":"CM McMahon","year":"2019","unstructured":"McMahon, C. M. et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 3, 1581\u20131585 (2019).","journal-title":"Blood Adv."},{"key":"26849_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-488114","volume":"123","author":"M Bots","year":"2014","unstructured":"Bots, M. et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 123, 1341\u20131352 (2014).","journal-title":"Blood"},{"key":"26849_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","volume":"167","author":"DB Sykes","year":"2016","unstructured":"Sykes, D. B. et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 167, 171\u2013186 (2016).","journal-title":"Cell"},{"key":"26849_CR14","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","volume":"33","author":"S Christian","year":"2019","unstructured":"Christian, S. et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia 33, 2403\u20132415 (2019).","journal-title":"Leukemia"},{"key":"26849_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605\u2013611 (2012).","journal-title":"Nat. Med."},{"key":"26849_CR16","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1016\/j.celrep.2018.03.012","volume":"22","author":"A Maiques-Diaz","year":"2018","unstructured":"Maiques-Diaz, A. et al. Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia. Cell Rep. 22, 3641\u20133659 (2018).","journal-title":"Cell Rep."},{"key":"26849_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010).","journal-title":"Cancer Cell"},{"key":"26849_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225\u2013234 (2010).","journal-title":"Cancer Cell"},{"key":"26849_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","volume":"7","author":"K Yen","year":"2017","unstructured":"Yen, K. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7, 478\u2013493 (2017).","journal-title":"Cancer Discov."},{"key":"26849_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130, 722\u2013731 (2017).","journal-title":"Blood"},{"key":"26849_CR21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","volume":"130","author":"MD Amatangelo","year":"2017","unstructured":"Amatangelo, M. D. et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130, 732\u2013741 (2017).","journal-title":"Blood"},{"key":"26849_CR22","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386\u20132398 (2018).","journal-title":"N. Engl. J. Med."},{"key":"26849_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","volume":"4","author":"AT Fathi","year":"2018","unstructured":"Fathi, A. T. et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: Analysis of a phase 1\/2 study. JAMA Oncol. 4, 1106\u20131110 (2018).","journal-title":"JAMA Oncol."},{"key":"26849_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04384-5","volume":"9","author":"J Lehmann-Che","year":"2018","unstructured":"Lehmann-Che, J. et al. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nat. Commun. 9, 2047 (2018).","journal-title":"Nat. Commun."},{"key":"26849_CR25","doi-asserted-by":"crossref","unstructured":"Iaccarino, L. et al. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. Am. J. Hematol. 94, 1091\u20131097 (2019).","DOI":"10.1002\/ajh.25573"},{"key":"26849_CR26","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/leu.2016.69","volume":"30","author":"V Madan","year":"2016","unstructured":"Madan, V. et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia 30, 1672\u20131681 (2016).","journal-title":"Leukemia"},{"key":"26849_CR27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood.V92.4.1172","volume":"92","author":"W Ding","year":"1998","unstructured":"Ding, W. et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 92, 1172\u20131183 (1998).","journal-title":"Blood"},{"key":"26849_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/sj.leu.2404118","volume":"20","author":"RE Gallagher","year":"2006","unstructured":"Gallagher, R. E. et al. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia 20, 556\u2013562 (2006).","journal-title":"Leukemia"},{"key":"26849_CR29","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood-2012-01-407601","volume":"120","author":"RE Gallagher","year":"2012","unstructured":"Gallagher, R. E. et al. Treatment-influenced associations of PML-RAR mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood 120, 2098\u20132108 (2012).","journal-title":"Blood"},{"key":"26849_CR30","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","volume":"24","author":"L Quek","year":"2018","unstructured":"Quek, L. et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat. Med. 24, 1167\u20131177 (2018).","journal-title":"Nat. Med."},{"key":"26849_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","volume":"559","author":"AM Intlekofer","year":"2018","unstructured":"Intlekofer, A. M. et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature 559, 125\u2013129 (2018).","journal-title":"Nature"},{"key":"26849_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","volume":"8","author":"JJ Harding","year":"2018","unstructured":"Harding, J. J. et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase Inhibition. Cancer Discov. 8, 1540\u20131547 (2018).","journal-title":"Cancer Discov."},{"key":"26849_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.stem.2019.07.001","volume":"25","author":"MD McKenzie","year":"2019","unstructured":"McKenzie, M. D. et al. Interconversion between tumorigenic and differentiated states in acute myeloid leukemia. Cell Stem Cell 25, 258\u2013272 (2019).","journal-title":"Cell Stem Cell"},{"key":"26849_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.stem.2019.07.005","volume":"25","author":"S Bamezai","year":"2019","unstructured":"Bamezai, S. & Buske, C. Cutting off leukemogenesis: hydra-like plasticity of mature leukemic cells. Cell Stem Cell 25, 167\u2013168 (2019).","journal-title":"Cell Stem Cell"},{"key":"26849_CR35","doi-asserted-by":"publisher","first-page":"D780","DOI":"10.1093\/nar\/gky1020","volume":"47","author":"J Choi","year":"2019","unstructured":"Choi, J. et al. Haemopedia RNA-seq: a database of gene expression during haematopoiesis in mice and humans. Nucleic Acids Res. 47, D780\u2013D785 (2019).","journal-title":"Nucleic Acids Res."},{"key":"26849_CR36","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1084\/jem.20050548","volume":"201","author":"H Iwasaki","year":"2005","unstructured":"Iwasaki, H. et al. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J. Exp. Med. 201, 1891\u20131897 (2005).","journal-title":"J. Exp. Med."},{"key":"26849_CR37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ni.3006","volume":"15","author":"B Becher","year":"2014","unstructured":"Becher, B. et al. High-dimensional analysis of the murine myeloid cell system. Nat. Immunol. 15, 1181\u20131189 (2014).","journal-title":"Nat. Immunol."},{"key":"26849_CR38","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1182\/blood-2016-03-700336","volume":"127","author":"J Lahoz-Beneytez","year":"2016","unstructured":"Lahoz-Beneytez, J. et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood 127, 3431\u20133438 (2016).","journal-title":"Blood"},{"key":"26849_CR39","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2016-09-687889","volume":"129","author":"JD Crispino","year":"2017","unstructured":"Crispino, J. D. & Horwitz, M. S. GATA factor mutations in hematologic disease. Blood 129, 2103\u20132110 (2017).","journal-title":"Blood"},{"key":"26849_CR40","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1084\/jem.20020170","volume":"195","author":"R Hirasawa","year":"2002","unstructured":"Hirasawa, R. et al. Essential and instructive roles of GATA factors in eosinophil development. J. Exp. Med. 195, 1379\u20131386 (2002).","journal-title":"J. Exp. Med."},{"key":"26849_CR41","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1084\/jem.20020656","volume":"195","author":"C Yu","year":"2002","unstructured":"Yu, C. et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J. Exp. Med. 195, 1387\u20131395 (2002).","journal-title":"J. Exp. Med."},{"key":"26849_CR42","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ni.3412","volume":"17","author":"R Drissen","year":"2016","unstructured":"Drissen, R. et al. Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. Nat. Immunol. 17, 666\u2013676 (2016).","journal-title":"Nat. Immunol."},{"key":"26849_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng1566","volume":"37","author":"Z Li","year":"2005","unstructured":"Li, Z. et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat. Genet. 37, 613\u2013619 (2005).","journal-title":"Nat. Genet."},{"key":"26849_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ni.3225","volume":"16","author":"SE Bettigole","year":"2015","unstructured":"Bettigole, S. E. et al. The transcription factor XBP1 is selectively required for eosinophil differentiation. Nat. Immunol. 16, 829\u2013837 (2015).","journal-title":"Nat. Immunol."},{"key":"26849_CR45","first-page":"135","volume":"26","author":"K Kishi","year":"1998","unstructured":"Kishi, K. et al. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp. Hematol. 26, 135\u2013142 (1998).","journal-title":"Exp. Hematol."},{"key":"26849_CR46","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7, 716\u2013735 (2017).","journal-title":"Cancer Discov."},{"key":"26849_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","volume":"34","author":"AL Boyd","year":"2018","unstructured":"Boyd, A. L. et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML Recurrence. Cancer Cell 34, 483\u2013498 (2018).","journal-title":"Cancer Cell"},{"key":"26849_CR48","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"26849_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MOH.0000000000000293","volume":"24","author":"R Willebrand","year":"2017","unstructured":"Willebrand, R. & Voehringer, D. Regulation of eosinophil development and survival. Curr. Opin. Hematol. 24, 9\u201315 (2017).","journal-title":"Curr. Opin. Hematol."},{"key":"26849_CR50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","volume":"49","author":"M Guilliams","year":"2018","unstructured":"Guilliams, M., Mildner, A. & Yona, S. Developmental and functional heterogeneity of monocytes. Immunity 49, 595\u2013613 (2018).","journal-title":"Immunity"},{"key":"26849_CR51","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.15609","volume":"184","author":"J Galeotti","year":"2019","unstructured":"Galeotti, J. & Coombs, C. C. Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations. Br. J. Haematol. 184, 496 (2019).","journal-title":"Br. J. Haematol."},{"key":"26849_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrd3838","volume":"12","author":"PC Fulkerson","year":"2013","unstructured":"Fulkerson, P. C. & Rothenberg, M. E. Targeting eosinophils in allergy, inflammation and beyond. Nat. Rev. Drug Discov. 12, 117\u2013129 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"26849_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171461","volume":"325","author":"MA Rieger","year":"2009","unstructured":"Rieger, M. A., Hoppe, P. S., Smejkal, B. M., Eitelhuber, A. C. & Schroeder, T. Hematopoietic cytokines can instruct lineage choice. Science 325, 217\u2013218 (2009).","journal-title":"Science"},{"key":"26849_CR54","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506\u2013519 e505 (2017).","journal-title":"Cancer Cell"},{"key":"26849_CR55","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 (2019).","journal-title":"Cell"},{"key":"26849_CR56","doi-asserted-by":"crossref","unstructured":"Nam, A. S., Chaligne, R., Landau, D. A. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat. Rev. Genet. 22, 3\u201318 (2020).","DOI":"10.1038\/s41576-020-0265-5"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26849-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T11:16:20Z","timestamp":1675854980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26849-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26849"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26849-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6546"}}